In particular, gain-of-function mutations in the Su(var)3-9, Enhancer-of-zeste and Trithorax (SET) domain, including tyrosine 641 (Y641), account for 22% of GCB DLBCL, supporting the utility of EZH2 intervention for the treatment of this subtype [3]. Here, EZH2 is linked to diffuse large B-cell lymphoma.